

Supplement Table 1. Serious Adverse Events

Body System and Adverse Event <sup>a</sup>	Total Number (%) of Subjects with Serious Adverse Event				
	Pooled Placebo (N=63)	Laq 0.5 mg (N=29)	Laq 1.0 mg (N=30)	Laq 1.5 mg (N=29)	Laq 2.0 mg (N=29)
All	7 (11.1)	3 (10.3)	8 (26.7)	1 (3.4)	3 (10.3)
Endocrine disorders	0	0	1 (3.3)	0	0
Goitre	0	0	1 (3.3)	0	0
Gastrointestinal disorders	2 (3.2)	3 (10.3)	5 (16.7)	1 (3.4)	1 (3.4)
Abdominal pain	0	0	1 (3.3)	0	0
Abdominal pain lower	0	0	1 (3.3)	0	0
Crohn's disease <sup>b</sup>	1 (1.6)	2 (6.9)	3 (10.0)	1 (3.4)	1 (3.4)
Inguinal hernia	0	1 (3.4)	0	0	0
Gastrointestinal hemorrhage	1 (1.6)	0	0	0	0
General disorder and administration site conditions	0	0	0	0	1 (3.4)
Non-cardiac disorder	0	0	0	0	1 (3.4)
Infections and Infestations	1 (1.6)	0	2 (6.7)	0	0
Abdominal abscess	1 (1.6)	0	1 (3.3)	0	0
Gastroenteritis viral	0	0	1 (3.3)	0	0
Investigations	0	0	0	1 (3.4)	0
Blood amylase increased	0	0	0	1 (3.4)	0
Metabolism and nutrition disorders	1 (1.6)	0	0	0	0
Hypoalbuminaemia	1 (1.6)	0	0	0	0
Nervous system disorders	1 (1.6)	0	0	1 (3.4)	0
Headache	0	0	0	1 (3.4)	0
Presyncope	1 (1.6)	0	0	0	0
Reproductive system and breast disorders	0	0	0	0	1 (3.4)
Dysmenorrhoea	0	0	0	0	1 (3.4)
Surgical and medical procedures	1 (1.6)	0	2 (6.7)	0	0
Intestinal resection	1 (1.6)	0	1 (3.3)	0	0
Proctocolectomy	0	0	1 (3.3)	0	0
Ileostomy	1 (1.6)	0	1 (3.3)	0	0
Vascular disorders	1 (1.6)	0	0	0	0
Deep vein thrombosis	1 (1.6)	0	0	0	0